


THURSDAY, OCTOBER 12, 7:30 – 8:30 PM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

S2209

Recently activated **S2209** is SWOG’s high-priority phase III trial for patients newly diagnosed with multiple myeloma who are not candidates for transplant. Members at sites opening (or considering opening) the trial should plan to attend the **S2209 kickoff session**.

S2209: A Phase III Randomized Trial for “Frail” or a Subset of “Intermediate Fit” Newly Diagnosed Multiple Myeloma (NDMM) Patients Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance

STUDY CHAIRS



Sikander Ailawadhi, MD



Jing Christine Ye, MD, MS




Brea Lipe, MD



Kristina Gowin, DO (QOL/PRO)



Thomas Chauncey, MD, PhD (VA Cmte)



This three-arm trial aims to meet unmet needs in frail and other real-world patients with NDMM. It’s designed to maximize enrollment among patients often excluded from prospective clinical trials.

Trial objectives include comparisons of patient-reported quality-of-life outcomes and comparisons of rates of minimal residual disease (MRD).

A smooth launch of this trial requires careful coordination of its multiple components. This kickoff meeting will provide critical support to sites getting ready to enroll patients to S2209.

COME AND HAVE YOUR QUESTIONS ANSWERED!